Journal
PEDIATRIC INFECTIOUS DISEASE JOURNAL
Volume 38, Issue 3, Pages 275-279Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/INF.0000000000002237
Keywords
anidulafungin; invasive candidiasis; candidemia; pediatric
Categories
Funding
- Pfizer
Ask authors/readers for more resources
Background: Treatment with an echinocandin is recommended as first-line therapy for patients with invasive candidiasis (ICC) including candidemia. Little is known about the efficacy and safety of anidulafungin in children with ICC. Methods: Eligible patients with ICC 2 to < 18 years old were enrolled into this prospective, open-label, noncomparative, international study (NCT00761267) and received anidulafungin for 10-35 days (3 mg/kg on day 1, 1.5 mg/kg daily thereafter). Safety was assessed through week 6 follow- up. Efficacy, measured by global response (based on clinical and microbiologic responses), was assessed at end of intravenous treatment (EOIVT), end of treatment, weeks 2 and 6 follow-up. Results: Forty-nine patients (n = 19, 2 to < 5 years; n = 30, 5 to < 18 years) received = 1 dose of anidulafungin (median 11 days; range 1-35 days) and were assessed for safety. Among 48 patients with a Candida species isolated, C. albicans (37.5%), C. parapsilosis (25.0%), C. tropicalis (14.6%) and C. lusitaniae (10.4%) were the most frequent Candida spp. All patients reported = 1 treatment-emergent adverse event, with diarrhea (22.4%), vom-iting (24.5%) and pyrexia (18.4%) being most frequent. Five patients discontinued treatment because of adverse events, of which 4 discontinuations were considered related to anidulafungin. All-cause mortality was 8.2% (4/49) by EOIVT and 14.3% (7/49) by week 6 follow-up. None of 7 deaths during the study period were considered treatment related. Global response success rate was 70.8% at EOIVT. Conclusions: These data support the use of anidulafungin as a treatment option for ICC in children 2 to < 18 years old at the studied dose.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available